Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674247 | 0.86 | CTSL (0.69) | CTSLATMMETTL3ALDH1A1LMNA | |
| SCHEMBL27999578 | 0.84 | CTSL (0.70) | CTSLATMMETTL3ALDH1A1LMNA | |
| SCHEMBL941203 | 0.82 | CTSL (0.68) | CTSLATMMETTL3SMN1; SMN2CTSB | |
| SCHEMBL27596090 | 0.82 | CTSL (0.68) | CTSLATMMETTL3ALDH1A1LMNA | |
| SCHEMBL2675573 | 0.82 | CTSL (0.73) | CTSLATMMETTL3ALDH1A1LMNA | |
| SCHEMBL25408895 | 0.81 | CTSL (0.66) | CTSLATMMETTL3ALDH1A1LMNA | |
| SCHEMBL27950773 | 0.81 | CTSL (1.00) | CTSLATMMETTL3ALDH1A1LMNA | |
| SCHEMBL27647421 | 0.81 | CTSL (0.71) | CTSLATMMETTL3ALDH1A1LMNA | |
| SCHEMBL9134153 | 0.79 | CTSL (0.64) | CTSLATMMETTL3ALDH1A1LMNA | |
| SCHEMBL8320460 | 0.79 | CTSL (0.69) | CTSLATMMETTL3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100484928-C | thiadiazoline derivatives | KYOWA HAKKO KOGYO KK FUJI PHOT (JP) | 2009-05-06 | — | — | CN | disclosed |
| US-20050113283-A1 | Methods of treating conditions associated with an EDG-4 receptor | MANIV ENERGY CAPITAL | 2005-05-26 | — | — | US | disclosed |
| CN-1617864-A | thiadiazoline derivatives | KYOWA HAKKO KOGYO KK (JP) | 2005-05-18 | — | — | CN | disclosed |
| EP-1513522-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | SRI INTERNATIONAL (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003062392-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | CERETEK LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113283-A1 | Methods of treating conditions associated with an EDG-4 receptor | EDNRA, EDNRB, ESRRG | CTSL 1097/4885ATM 4834/4885METTL3 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.